Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
NS6740 is an α7 nicotinic acetylcholine receptor-selective partial agonist with low efficacy for channel activation, capable of promoting the stable conversion of the receptors to nonconducting (desensitized) states that can be reactivated with the application of positive allosteric modulators (PAMs). In spite of its low efficacy for channel activation, NS6740 is an effective activator of the cholinergic anti-inflammatory pathway. We observed that the concentration-response relationships for channel activation, both when applied alone and when co-applied with the PAM PNU-120596 are inverted-U shaped with inhibitory/desensitizing activities dominant at high concentrations. We evaluated the potential importance of recently identified binding sites for allosteric activators and tested the hypotheses that the stable desensitization produced by NS6740 may be due to binding to these sites. Our experiments were guided by molecular modeling of NS6740 binding to both the allosteric and orthosteric activation sites on the receptor. Our results indicate that with α7C190A mutants, which have compromised orthosteric activation sites, NS6740 may work at the allosteric activation sites to promote transient PAM-dependent currents but not the stable desensitization seen with wild-type α7 receptors. Modeling NS6740 in the orthosteric binding sites identified S36 as an important residue for NS6740 binding and predicted that an S36V mutation would limit NS6740 activity. The efficacy of NS6740 for α7S36V receptors was reduced to zero, and applications of the compound to α7S36V receptors failed to induce the desensitization observed with wild-type receptors. The results indicate that the unique properties of NS6740 are due primarily to binding at the sites for orthosteric agonists.
Aickin,
Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.
1996, Pubmed
Aickin,
Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.
1996,
Pubmed Aldrich,
A reinterpretation of mammalian sodium channel gating based on single channel recording.
,
Pubmed Bagdas,
New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs.
2018,
Pubmed Bagdas,
The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain.
2016,
Pubmed Briggs,
Role of channel activation in cognitive enhancement mediated by alpha7 nicotinic acetylcholine receptors.
2009,
Pubmed
,
Xenbase Cannon,
The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.
2013,
Pubmed Castro,
alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability.
1995,
Pubmed Cecon,
Quantitative assessment of oligomeric amyloid β peptide binding to α7 nicotinic receptor.
2019,
Pubmed Chiodo,
A possible desensitized state conformation of the human α7 nicotinic receptor: A molecular dynamics study.
2017,
Pubmed de Jonge,
The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation.
2007,
Pubmed Di Cesare Mannelli,
Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation.
2014,
Pubmed El Nebrisi,
Curcumin Acts as a Positive Allosteric Modulator of α7-Nicotinic Acetylcholine Receptors and Reverses Nociception in Mouse Models of Inflammatory Pain.
2018,
Pubmed
,
Xenbase Esterhuysen,
Trifluoromethyl: An Amphiphilic Noncovalent Bonding Partner.
2017,
Pubmed Friesner,
Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.
2006,
Pubmed Fucile,
Fractional Ca(2+) current through human neuronal alpha7 nicotinic acetylcholine receptors.
2003,
Pubmed Grønlien,
Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes.
2007,
Pubmed
,
Xenbase Gulsevin,
In Silico Modeling of the α7 Nicotinic Acetylcholine Receptor: New Pharmacological Challenges Associated with Multiple Modes of Signaling.
2020,
Pubmed Gulsevin,
Allosteric Agonism of α7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site.
2019,
Pubmed
,
Xenbase Halevi,
Conservation within the RIC-3 gene family. Effectors of mammalian nicotinic acetylcholine receptor expression.
2003,
Pubmed
,
Xenbase Henchman,
Asymmetric structural motions of the homomeric alpha7 nicotinic receptor ligand binding domain revealed by molecular dynamics simulation.
2003,
Pubmed Hibbs,
Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal alpha7 nicotinic acetylcholine receptor.
2009,
Pubmed Horenstein,
Anti-inflammatory Silent Agonists.
2017,
Pubmed Horenstein,
Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: SEPARATION OF DIRECT ALLOSTERIC ACTIVATION AND POSITIVE ALLOSTERIC MODULATION.
2016,
Pubmed
,
Xenbase Isaacson,
Point-to-point ligand-receptor interactions across the subunit interface modulate the induction and stabilization of conformational states of alpha7 nAChR by benzylidene anabaseines.
2013,
Pubmed
,
Xenbase Jordan,
Discovery and development of varenicline for smoking cessation.
2018,
Pubmed Kabbani,
Beyond the Channel: Metabotropic Signaling by Nicotinic Receptors.
2018,
Pubmed King,
Alpha 7 nicotinic receptors attenuate neurite development through calcium activation of calpain at the growth cone.
2018,
Pubmed Kong,
Alpha 7 nicotinic acetylcholine receptor agonist GTS-21 mitigates isoflurane-induced cognitive impairment in aged rats.
2015,
Pubmed Kulkarni,
Microwave-assisted Expeditious and Efficient Synthesis of Cyclopentene Ring-fused Tetrahydroquinoline Derivatives Using Three-component Povarov Reaction.
2013,
Pubmed Law,
A gating mechanism proposed from a simulation of a human alpha7 nicotinic acetylcholine receptor.
2005,
Pubmed Leiser,
A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits.
2009,
Pubmed Li,
Ligand-binding domain of an α7-nicotinic receptor chimera and its complex with agonist.
2011,
Pubmed Miller,
Allosterically Potentiated α7 Nicotinic Acetylcholine Receptors: Reduced Calcium Permeability and Current-Independent Control of Intracellular Calcium.
2020,
Pubmed
,
Xenbase Nanclares,
Dual Antidepressant Duloxetine Blocks Nicotinic Receptor Currents, Calcium Signals and Exocytosis in Chromaffin Cells Stimulated with Acetylcholine.
2018,
Pubmed Noviello,
Structure and gating mechanism of the α7 nicotinic acetylcholine receptor.
2021,
Pubmed Papke,
Cholinergic Receptors and Addiction.
2020,
Pubmed Papke,
Differing Activity Profiles of the Stereoisomers of 2,3,5,6TMP-TQS, a Putative Silent Allosteric Modulator of α7 nAChR.
2020,
Pubmed Papke,
Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states.
2018,
Pubmed
,
Xenbase Papke,
NS6740, an α7 nicotinic acetylcholine receptor silent agonist, disrupts hippocampal synaptic plasticity.
2018,
Pubmed
,
Xenbase Papke,
The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor.
2015,
Pubmed
,
Xenbase Papke,
Merging old and new perspectives on nicotinic acetylcholine receptors.
2014,
Pubmed Papke,
The activity of GAT107, an allosteric activator and positive modulator of α7 nicotinic acetylcholine receptors (nAChR), is regulated by aromatic amino acids that span the subunit interface.
2014,
Pubmed
,
Xenbase Papke,
Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
2011,
Pubmed
,
Xenbase Papke,
Tricks of perspective: insights and limitations to the study of macroscopic currents for the analysis of nAChR activation and desensitization.
2010,
Pubmed
,
Xenbase Papke,
Working with OpusXpress: methods for high volume oocyte experiments.
2010,
Pubmed
,
Xenbase Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase Papke,
The correction of alpha7 nicotinic acetylcholine receptor concentration-response relationships in Xenopus oocytes.
1998,
Pubmed
,
Xenbase Papke,
Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit.
1994,
Pubmed
,
Xenbase Peng,
Multiple modes of α7 nAChR noncompetitive antagonism of control agonist-evoked and allosterically enhanced currents.
2013,
Pubmed
,
Xenbase Pieschl,
Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.
2017,
Pubmed Pismataro,
Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation.
2020,
Pubmed
,
Xenbase Qi,
High-fat diet-induced obesity affects alpha 7 nicotine acetylcholine receptor expressions in mouse lung myeloid cells.
2020,
Pubmed Rosas-Ballina,
Cholinergic control of inflammation.
2009,
Pubmed Scabia,
ICH3, a selective alpha7 nicotinic acetylcholine receptor agonist, modulates adipocyte inflammation associated with obesity.
2020,
Pubmed Schaftenaar,
Molden: a pre- and post-processing program for molecular and electronic structures.
2000,
Pubmed Séguéla,
Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium.
1993,
Pubmed
,
Xenbase Sitzia,
Voltage- and Temperature-Dependent Allosteric Modulation of α7 Nicotinic Receptors by PNU120596.
2011,
Pubmed Spurny,
Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor.
2015,
Pubmed
,
Xenbase Stokes,
Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant β Subunits Acquire Sensitivity to α7-Selective Positive Allosteric Modulators.
2019,
Pubmed
,
Xenbase Thakur,
Expeditious synthesis, enantiomeric resolution, and enantiomer functional characterization of (4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS): an allosteric agonist-positive allosteric modulator of α7 nicotinic acetylcholine receptors.
2013,
Pubmed
,
Xenbase Thomsen,
The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia.
2012,
Pubmed Timmermann,
Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.
2012,
Pubmed
,
Xenbase Ulleryd,
Stimulation of alpha 7 nicotinic acetylcholine receptor (α7nAChR) inhibits atherosclerosis via immunomodulatory effects on myeloid cells.
2019,
Pubmed Wallace,
Drug targets for cognitive enhancement in neuropsychiatric disorders.
2011,
Pubmed Walling,
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.
2016,
Pubmed Wazea,
Galantamine anti-colitic effect: Role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways.
2018,
Pubmed Williams,
Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.
2011,
Pubmed Williams,
Investigation of the molecular mechanism of the α7 nicotinic acetylcholine receptor positive allosteric modulator PNU-120596 provides evidence for two distinct desensitized states.
2011,
Pubmed
,
Xenbase Yang,
Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation.
2019,
Pubmed Zhu,
Anti-inflammatory effects of α7-nicotinic ACh receptors are exerted through interactions with adenylyl cyclase-6.
2021,
Pubmed
